

**Table 1. Global Prospective HoLISTIC Hodgkin Lymphoma Clinical Trials (individual patient data).**

Group/Study Name (ref)	Years accrual	Pt number	Author, Year(s) published	Reference(s)
<b>Adult Early Stage</b>				
<i>EORTC H9U</i>	1998 – 2002	808	Ferne 2017	[1]
<i>NCI-C/ECOG</i>	1994 – 2002	276	Meyer 2005 and Meyer 2012	[2, 3]
<i>*ECOG 2496</i>	1999 – 2006	281	Gordon 2012, Evens 2013, and Advani 2015	[4-6]
<i>EORTC H10</i>	2006 – 2009	1950	Raemaekers 2014 and Andre 2017	[7, 8]
<i>RAPID</i>	2003 – 2010	602	Radford 2015	[9]
<i>*RATHL</i>	2008 – 2012	500	Johnson 2016	[10]
<b>Pediatric Low and Intermediate Risk (stages I-II)</b>				
<i>AHOD0031</i>	2002 – 2009	1114	Friedman 2014	[11]
<i>AHOD0431</i>	2006 – 2012	287	Keller 2018	[12]
<b>Adult Early Stage and Pediatric Low-Intermediate Risk (total): 5,818 patients</b>				
<b>Adult Advanced Stage</b>				
<i>Italian IIL HD9601</i>	1996 – 2000	355	Gobbi 2005 and Chisesi 2011	[13, 14]
<i>Italian HD2000</i>	2000 – 2007	307	Federico 2009 and Merli 2016	[15, 16]
<i>UK ISRCTN</i>	1998 – 2006	520	Hoskin 2009	[17]
<i>*ECOG 2496</i>	1999 – 2006	513	Gordon 2012, Evens 2013, and Advani 2015	[4-6]
<i>SWOG 0816</i>	2009 – 2012	371	Press 2016 and Stephens 2019	[18, 19]
<i>*RATHL</i>	2008 – 2012	712	Johnson 2016	[10]
<i>HD0801 IIL</i>	2008 – 2013	519	Zinzani 2017	[20]
<i>GITIL HD0607</i>	2008 – 2014	780	Gallamini 2018	[21]
<b>Pediatric Intermediate and High Risk (stages III-IV)</b>				
<i>AHOD0031</i>	2002 - 2009	608	Friedman 2014	[11]
<i>AHOD0831</i>	2009 – 2013	165	Kelly 2019	[22]
<b>Adult Advanced Stage and Pediatric Intermediate-High Risk (total): 4,850 patients</b>				
<i>*adult studies that included both early- and advanced-stage patients</i>				

**Table 2. Global HoLISTIC Hodgkin Lymphoma Registries and Prospective Cohorts (individual patient data).**

Registry Name (ref)	No. Pts	Yrs Diagnosis	Author, Year(s) published	Reference
<i>Princess Margaret Hospital</i>	1200	2000-2017	Hahn 2017	[23]
<i>Iowa/Mayo Clinic SPORE</i>	700	2002-2017	Cerhan 2017	[24]
<i>BC Cancer</i>	1905	2000-2015	Hapgood 2016	[25]
<i>Australia</i>	470	2016-present	Lymphoma, Related Diseases Registry 2022	[26]
<i>Stanford Registry*</i>	395	1995-2019	n/a	n/a
<b>TOTAL: 4275 pts</b>				
Abbreviations: Ref, references; No, number; pts; patients; BC, British Columbia.				
*Early stage only; transfer of advanced stage patients in process				

## References

1. Ferme, C., et al., *ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Etude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial*. Eur J Cancer, 2017. **81**: p. 45-55.
2. Meyer, R.M., et al., *Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group*. J Clin Oncol, 2005. **23**(21): p. 4634-42.
3. Meyer, R.M., et al., *ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma*. N Engl J Med, 2012. **366**(5): p. 399-408.
4. Gordon, L.I., et al., *Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)*. J Clin Oncol, 2013. **31**(6): p. 684-91.
5. Advani, R.H., et al., *Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial*. J Clin Oncol, 2015. **33**(17): p. 1936-42.
6. Evens, A.M., et al., *The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496*. Br J Haematol, 2013. **161**(1): p. 76-86.
7. Andre, M.P.E., et al., *Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial*. J Clin Oncol, 2017. **35**(16): p. 1786-1794.
8. Raemaekers, J.M., et al., *Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial*. J Clin Oncol, 2014. **32**(12): p. 1188-94.
9. Radford, J., et al., *Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma*. N. Engl. J. Med, 2015. **372**(17): p. 1598-1607.
10. Johnson, P., et al., *Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma*. N Engl J Med, 2016. **374**(25): p. 2419-29.
11. Keller, F.G., et al., *Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group*. Cancer, 2018.
12. Friedman, D.L., et al., *Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031*. J Clin Oncol, 2014. **32**(32): p. 3651-8.
13. Chisesi, T., et al., *Long-term follow-up analysis of HD9601 trial comparing ABVD versus Stanford V versus MOPP/EBV/CAD in patients with newly diagnosed advanced-stage Hodgkin's lymphoma: a study from the Intergruppo Italiano Linfomi*. J Clin Oncol, 2011. **29**(32): p. 4227-33.
14. Gobbi, P.G., et al., *ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi*. J Clin Oncol, 2005. **23**(36): p. 9198-207.
15. Federico, M., et al., *ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial*. J Clin Oncol, 2009. **27**(5): p. 805-11.
16. Merli, F., et al., *Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi*. J Clin Oncol, 2016. **34**(11): p. 1175-81.
17. Hoskin, P.J., et al., *Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244*. J Clin Oncol, 2009. **27**(32): p. 5390-6.
18. Press, O.W., et al., *US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816*. J Clin Oncol, 2016. **34**(17): p. 2020-7.

19. Stephens, D.M., et al., *Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma*. *Blood*, 2019. **134**(15): p. 1238-1246.
20. Zinzani, P.L., et al., *Interim Positron Emission Tomography Response-Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study*. *J Clin Oncol*, 2016. **34**(12): p. 1376-85.
21. Gallamini, A., et al., *Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial*. *J Clin Oncol*, 2018. **36**(5): p. 454-462.
22. Kelly, K.M., et al., *Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children's Oncology Group*. *Br J Haematol*, 2019. **187**(1): p. 39-48.
23. Hahn, E., et al., *Late Cardiac Toxicity After Mediastinal Radiation Therapy for Hodgkin Lymphoma: Contributions of Coronary Artery and Whole Heart Dose-Volume Variables to Risk Prediction*. *Int J Radiat Oncol Biol Phys*, 2017. **98**(5): p. 1116-1123.
24. Cerhan, J.R., et al., *Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study*. *Int J Epidemiol*, 2017. **46**(6): p. 1753-1754i.
25. Hapgood, G., et al., *Evaluation of the Risk of Relapse in Classical Hodgkin Lymphoma at Event-Free Survival Time Points and Survival Comparison With the General Population in British Columbia*. *J Clin Oncol*, 2016. **34**(21): p. 2493-500.
26. Lymphoma and I. Related Diseases Registry, *Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry*. *BMC Med Res Methodol*, 2022. **22**(1): p. 266.